Moreover, immunohistochemistry (IHC) results showed decreased Ki67 expression but increased cleaved caspase-3 expression in tumors treated with the combination of Roblitinib and CPI-169 compared with the untreated or single agent-treated tumors (Fig. 4D), suggesting that combination treatment elicited a robust anti-cancer effect in vivo. The gene discussed is CASP3; the disease is cancer.